Breaking News
Get 50% Off 0
Unlock Premium Data: Up to 50% Off InvestingPro CLAIM SALE
Close

Grifols SA (0RDU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.18 -0.09    -0.97%
11:35:59 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  ES0171996087 
SEDOL:  BYZQYC0
  • Volume: 1,780,816
  • Bid/Ask: 8.88 / 9.24
  • Day's Range: 9.09 - 9.45
Grifols 9.18 -0.09 -0.97%

Grifols SA Company Profile

 
Get an in-depth profile of Grifols SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

23744

Equity Type

DRC

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Contact Information

Address Avinguda de la Generalitat, 152 Parc empresarial Can Sant Joan
Sant Cugat del Valles Barcelona, 08174
Spain
Phone 34 935 712 200
Fax 34 938 008 000

Top Executives

Name Age Since Title
Darcy Antonellis 61 2023 Non-Executive Director
Raimon Grifols Roura 60 2001 Vice-Chairman
Thomas H. Glanzmann 66 2006 Executive Chairman
Inigo Sánchez-Asiaín Mardones 60 2015 Independent Director
Carina Szpilka Lázaro 56 2015 Lead Independent Director
Nacho Abia 56 2024 CEO & Director
Víctor Grifols Deu 47 2016 Executive Director
Susana Gonzalez Rodriguez 48 2022 Independent Director
Anne-Catherine Berner - 2024 Independent Director
Claire Giraut - 2024 Independent Director
Montserrat Muñoz Abellana 56 2022 Independent Director
Tomas Daga Gelabert 68 2000 Independent External Director
Albert Grifols Coma-Cros 46 2023 Proprietary Director
Enriqueta Felip Font 60 2019 Independent Director
Juan Ignacio Twose Roura 78 1973 Member of the Advisory Committee
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GRLS Comments

Write your thoughts about Grifols SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Javier Gassol
Javier Gassol May 31, 2024 4:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Salva BB
Salva BB May 15, 2024 1:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ecobolsa.com/noticias/grifols-sube-resultados-valora-mercado.html
David Juan Plaza
David Juan Plaza May 15, 2024 11:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fin Subasta 10,180
Olga Ibex
Olga Ibex May 15, 2024 11:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Y el tapón en el 20?
May 14, 2024 3:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
¿Pero ha publicado ya las cuentas? O caemos un 5% porque si?
BABY OLI
BABY OLI May 06, 2024 3:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hola
Ivan Ortiz
Ivan Ortiz Apr 29, 2024 4:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
en la parte alta del canal que arranco desde los 15,9x, indicadores saliendo de la sobreventa y aparece acumulacion, analisis en objetivo10% en youtube o podcast de spotify, saluuu22222222
Blas Melendez Gomez
Blas Melendez Gomez Apr 16, 2024 4:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hola
Eu Cajal
Eu Cajal Apr 11, 2024 12:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
alguien lee o escribe en este chat o estoy en una realidad paralela desde semana santa?
Siguiendo Tendencias
Siguiendo Tendencias Mar 20, 2024 11:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nadie lo quiere oir pero es otra trampa alcista alrededor de los 9€, como la anterior en 12€, pero si alguien aprecia su dinero mas que la locura de la fe por una acción que se ande con ojo y revise el grafico para ver que puede pasar. El dinero no sabe de fe sino de hechos
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email